All In Biotech

Drug Trial Radar · NCT03746587

Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Last checked: Nov 19, 2026Latest source record: Jan 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

39

Actual

Start

Jun 6, 2018

Primary completion

Apr 1, 2020

Study completion Oct 15, 2021

Sponsor

Lead sponsor
ZevraDenmarkIndustry
Sponsor type
Industry
First posted
Nov 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, doubleblinded, randomized placebo-controlled study of arimoclomol in patients with Gaucher Disease Type 1 or 3

Conditions

  • Gaucher Disease, Type 1
  • Gaucher Disease, Type 3

Interventions

  • ArimoclomolDrug

    Arimoclomol in 3 different dosages

  • Placebo oral capsuleDrug

    Matching placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EndpointTime frame: 6 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Maulana Azad Medical College

    New Delhi, India

  • All India Institute of Medical Sciences

    New Delhi, India

  • King Edward Memorial Hospital

    Mumbai, Maharashtra, India

  • Jaslok Hospital and Reseach Centre

    Mumbai, Maharashtra, India

  • KEM HOSPITAL Research Centre

    Pune, Maharashtra, India

  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, India

  • Christian Medical College and Hospital.

    Vellore, Tamil Nadu, India

  • Institute of Child Health

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.